PE20071139A1 - Formulacion de liberacion sostenida que comprende octreotida y dos o mas polimeros de polilactido-co-glicolido - Google Patents
Formulacion de liberacion sostenida que comprende octreotida y dos o mas polimeros de polilactido-co-glicolidoInfo
- Publication number
- PE20071139A1 PE20071139A1 PE2006001665A PE2006001665A PE20071139A1 PE 20071139 A1 PE20071139 A1 PE 20071139A1 PE 2006001665 A PE2006001665 A PE 2006001665A PE 2006001665 A PE2006001665 A PE 2006001665A PE 20071139 A1 PE20071139 A1 PE 20071139A1
- Authority
- PE
- Peru
- Prior art keywords
- polymers
- sustained release
- polylactide
- release formulation
- formulation including
- Prior art date
Links
- 229920000642 polymer Polymers 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000013268 sustained release Methods 0.000 title abstract 2
- 239000012730 sustained-release form Substances 0.000 title abstract 2
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 title 1
- 108010016076 Octreotide Proteins 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 229960002700 octreotide Drugs 0.000 title 1
- 239000004480 active ingredient Substances 0.000 abstract 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 abstract 1
- 239000003006 anti-agglomeration agent Substances 0.000 abstract 1
- 239000007943 implant Substances 0.000 abstract 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 abstract 1
- 239000011859 microparticle Substances 0.000 abstract 1
- 239000000178 monomer Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Peptides Or Proteins (AREA)
- Polyesters Or Polycarbonates (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0526247A GB0526247D0 (en) | 2005-12-22 | 2005-12-22 | Organic compounds |
| EP06119086 | 2006-08-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20071139A1 true PE20071139A1 (es) | 2007-11-16 |
Family
ID=37772904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2006001665A PE20071139A1 (es) | 2005-12-22 | 2006-12-20 | Formulacion de liberacion sostenida que comprende octreotida y dos o mas polimeros de polilactido-co-glicolido |
Country Status (22)
| Country | Link |
|---|---|
| US (7) | US20090004283A1 (enExample) |
| EP (3) | EP1968549B1 (enExample) |
| JP (4) | JP2009520727A (enExample) |
| KR (5) | KR101245919B1 (enExample) |
| CN (1) | CN103251929A (enExample) |
| AR (1) | AR058591A1 (enExample) |
| AU (1) | AU2006328950B2 (enExample) |
| BR (2) | BRPI0620063B8 (enExample) |
| CA (1) | CA2631811C (enExample) |
| CL (1) | CL2018003398A1 (enExample) |
| EC (1) | ECSP088560A (enExample) |
| ES (2) | ES2755032T3 (enExample) |
| IL (1) | IL191842A0 (enExample) |
| IN (1) | IN2015DN03936A (enExample) |
| MA (1) | MA30064B1 (enExample) |
| NO (1) | NO20082988L (enExample) |
| PE (1) | PE20071139A1 (enExample) |
| PL (2) | PL1968549T3 (enExample) |
| PT (2) | PT1968549E (enExample) |
| RU (1) | RU2464972C2 (enExample) |
| TW (2) | TWI468172B (enExample) |
| WO (1) | WO2007071395A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE031550T2 (en) † | 2007-06-06 | 2017-07-28 | Debiopharm Res & Mfg Sa | Slow release pharmaceutical composition made of microparticles |
| US8470360B2 (en) * | 2008-04-18 | 2013-06-25 | Warsaw Orthopedic, Inc. | Drug depots having different release profiles for reducing, preventing or treating pain and inflammation |
| ES2324009B1 (es) * | 2007-11-23 | 2010-05-21 | Gp Pharm S.A. | Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo. |
| EP2247282B1 (en) | 2008-01-30 | 2014-08-20 | Novartis AG | Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers |
| AU2013201877B2 (en) * | 2008-01-30 | 2015-01-29 | Novartis Ag | Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers |
| ES3058497T3 (en) | 2008-09-17 | 2026-03-11 | Amryt Endo Inc | Pharmaceutical compositions comprising polypeptides and related methods of delivery |
| AU2015201581B2 (en) * | 2008-09-17 | 2017-03-09 | Amryt Endo, Inc. | Pharmaceutical Compositions and Related Methods of Delivery |
| US20100151033A1 (en) * | 2008-12-15 | 2010-06-17 | Novartis Ag | Octreotide depot formulation with constantly high exposure levels |
| US20100189763A1 (en) * | 2009-01-23 | 2010-07-29 | Heather Nettles | Controlled release systems from polymer blends |
| US20120022137A1 (en) * | 2010-07-21 | 2012-01-26 | Rivers Hongwen M | METHOD OF CONTROLLING INITIAL DRUG RELEASE OF siRNA FROM SUSTAINED-RELEASE IMPLANTS |
| GB201016433D0 (en) | 2010-09-30 | 2010-11-17 | Q Chip Ltd | Apparatus and method for making solid beads |
| GB201016436D0 (en) | 2010-09-30 | 2010-11-17 | Q Chip Ltd | Method of making solid beads |
| WO2012083026A1 (en) * | 2010-12-15 | 2012-06-21 | Evonik Degussa Corporation | Branched polyol polyesters, blends and pharmaceutical formulations comprising same |
| EP3199146B1 (en) * | 2011-04-25 | 2019-07-17 | Shan Dong Luye Pharmaceutical Co., Ltd. | Risperidone sustained release microsphere composition |
| CN102488619B (zh) * | 2011-12-05 | 2014-08-06 | 上海交通大学 | 连续生产艾塞那肽微球的装置及控制微球释放速度的方法 |
| US20170326073A1 (en) * | 2014-11-25 | 2017-11-16 | Cbc Co., Ltd. | Janus nanoparticle and method for producing the same |
| PL3253401T3 (pl) | 2015-02-03 | 2025-08-04 | Amryt Endo, Inc. | Leczenie akromegalii oktreotydem doustnym |
| CN107405059B (zh) * | 2015-06-26 | 2019-05-28 | 奥林巴斯株式会社 | 内窥镜电源供给系统 |
| US12396951B2 (en) * | 2016-12-27 | 2025-08-26 | Upexmed Co. Ltd. | Prevention of local tumor recurrence following surgery using sustainedand/or delayed release of medicaments contained in micro-particles |
| KR102142026B1 (ko) * | 2017-05-31 | 2020-08-06 | 주식회사 대웅제약 | 방출제어가 용이한 서방성 약물 미립자의 제조방법 |
| MX2022002980A (es) | 2019-09-16 | 2022-04-06 | Amgen Inc | Metodo para la esterilizacion externa de un dispositivo de suministro de farmacos. |
| CN111214643A (zh) * | 2020-03-11 | 2020-06-02 | 苏州善湾生物医药科技有限公司 | 一种基于皮下凝胶缓释的奥曲肽组合物、制备方法及应用 |
| CN115551485B (zh) * | 2020-05-08 | 2024-09-24 | M技术株式会社 | 均匀分散有生理活性物质的微球及含有其的缓释制剂 |
| US11617720B2 (en) | 2020-05-08 | 2023-04-04 | M. Technique Co., Ltd. | Main agent uniformly dispersed microsphere and a sustained release formulation comprising the same |
| WO2021224999A1 (ja) * | 2020-05-08 | 2021-11-11 | エム・テクニック株式会社 | 生理活性物質が均一に分散されたマイクロスフェアー及びそれを含有する徐放性製剤 |
| US11141457B1 (en) | 2020-12-28 | 2021-10-12 | Amryt Endo, Inc. | Oral octreotide therapy and contraceptive methods |
| KR102464821B1 (ko) * | 2022-04-13 | 2022-11-09 | (주)인벤티지랩 | 목시덱틴을 포함하는 마이크로 입자 및 이를 포함하는 서방형 주사제 조성물 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) * | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| DE3062075D1 (en) | 1979-11-27 | 1983-03-24 | Sandoz Ag | Polypeptides, processes for their production, pharmaceutical compositions comprising said polypeptides and their use |
| US4675189A (en) * | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| US4897268A (en) * | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
| US5538739A (en) | 1989-07-07 | 1996-07-23 | Sandoz Ltd. | Sustained release formulations of water soluble peptides |
| PH30995A (en) * | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| HU221294B1 (en) * | 1989-07-07 | 2002-09-28 | Novartis Ag | Process for producing retarde compositions containing the active ingredient in a polymeric carrier |
| MY107937A (en) * | 1990-02-13 | 1996-06-29 | Takeda Chemical Industries Ltd | Prolonged release microcapsules. |
| CH683149A5 (fr) | 1991-07-22 | 1994-01-31 | Debio Rech Pharma Sa | Procédé pour la préparation de microsphères en matériau polymère biodégradable. |
| US5470582A (en) * | 1992-02-07 | 1995-11-28 | Syntex (U.S.A.) Inc. | Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles |
| KR100260632B1 (ko) * | 1992-12-28 | 2000-07-01 | 성재갑 | 이식형 소마토트로핀 조성물 |
| US5603960A (en) * | 1993-05-25 | 1997-02-18 | O'hagan; Derek T. | Preparation of microparticles and method of immunization |
| US5417982A (en) * | 1994-02-17 | 1995-05-23 | Modi; Pankaj | Controlled release of drugs or hormones in biodegradable polymer microspheres |
| US6447796B1 (en) * | 1994-05-16 | 2002-09-10 | The United States Of America As Represented By The Secretary Of The Army | Sustained release hydrophobic bioactive PLGA microspheres |
| ZA9711385B (en) * | 1996-12-20 | 1999-06-18 | Takeda Chemical Industries Ltd | Method of producing a sustained-release preparation |
| AR012448A1 (es) * | 1997-04-18 | 2000-10-18 | Ipsen Pharma Biotech | Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada |
| DE69833375D1 (de) * | 1997-06-04 | 2006-04-13 | Debio Rech Pharma Sa | Implantate zur gesteuerten freisetzung von pharmazeutischen wirkstoffen und verfahren zur herstellung |
| ES2169980B1 (es) * | 1999-12-17 | 2003-11-01 | Lipotec Sa | Microcapsulas para la liberacion prolongada de farmacos. |
| KR100392501B1 (ko) * | 2000-06-28 | 2003-07-22 | 동국제약 주식회사 | 다중 에멀젼법에 의한 서방출성 미립구의 제조방법 |
| EP1344520B1 (en) * | 2002-03-15 | 2007-10-03 | Alrise Biosystems GmbH | Microparticles and method for their production |
| MXPA05004927A (es) * | 2002-11-06 | 2005-09-08 | Alza Corp | Formulaciones de deposito de liberacion controlada. |
| US20040097419A1 (en) * | 2002-11-19 | 2004-05-20 | Holger Petersen | Organic compounds |
| KR100466637B1 (ko) * | 2003-06-26 | 2005-01-13 | 주식회사 펩트론 | 서방성 미립구의 혼합 제형을 연속한 단일 공정으로제조하는 방법 |
| JP2008518881A (ja) * | 2003-07-18 | 2008-06-05 | オークウッド ラボラトリーズ，エル．エル．シー． | 高分子組成物中の高分子の分子量低下、不純物形成およびゲル化の防止 |
| AU2004259209A1 (en) * | 2003-07-23 | 2005-02-03 | Pr Pharmaceuticals, Inc. | Controlled release compositions |
| MY158342A (en) * | 2003-11-14 | 2016-09-30 | Novartis Ag | Pharmaceutical composition |
| ATE424848T1 (de) * | 2004-08-12 | 2009-03-15 | Quest Pharmaceutical Services | Pharmazeutische zusammensetzungen für die kontrollierte freigabe von biologischen wirkstoffen |
-
2006
- 2006-12-20 RU RU2008129626/15A patent/RU2464972C2/ru active
- 2006-12-20 ES ES10175382T patent/ES2755032T3/es active Active
- 2006-12-20 PT PT68410596T patent/PT1968549E/pt unknown
- 2006-12-20 KR KR1020087014985A patent/KR101245919B1/ko active Active
- 2006-12-20 AU AU2006328950A patent/AU2006328950B2/en active Active
- 2006-12-20 BR BRPI0620063A patent/BRPI0620063B8/pt active IP Right Grant
- 2006-12-20 CN CN2013101523825A patent/CN103251929A/zh active Pending
- 2006-12-20 PE PE2006001665A patent/PE20071139A1/es not_active Application Discontinuation
- 2006-12-20 KR KR1020137004517A patent/KR101458728B1/ko active Active
- 2006-12-20 PL PL06841059T patent/PL1968549T3/pl unknown
- 2006-12-20 KR KR1020147031146A patent/KR20140133968A/ko not_active Ceased
- 2006-12-20 AR ARP060105668A patent/AR058591A1/es unknown
- 2006-12-20 US US12/158,345 patent/US20090004283A1/en not_active Abandoned
- 2006-12-20 JP JP2008546248A patent/JP2009520727A/ja active Pending
- 2006-12-20 KR KR1020137004518A patent/KR20130024987A/ko not_active Ceased
- 2006-12-20 BR BR122019027412A patent/BR122019027412B8/pt active IP Right Grant
- 2006-12-20 EP EP06841059.6A patent/EP1968549B1/en active Active
- 2006-12-20 WO PCT/EP2006/012313 patent/WO2007071395A1/en not_active Ceased
- 2006-12-20 EP EP19188892.4A patent/EP3603623A1/en not_active Withdrawn
- 2006-12-20 CA CA2631811A patent/CA2631811C/en active Active
- 2006-12-20 ES ES06841059.6T patent/ES2492641T3/es active Active
- 2006-12-20 PL PL10175382T patent/PL2359809T3/pl unknown
- 2006-12-20 EP EP10175382.0A patent/EP2359809B1/en active Active
- 2006-12-20 KR KR1020137004520A patent/KR20130024988A/ko not_active Ceased
- 2006-12-20 PT PT101753820T patent/PT2359809T/pt unknown
- 2006-12-20 IN IN3936DEN2015 patent/IN2015DN03936A/en unknown
- 2006-12-21 TW TW103107772A patent/TWI468172B/zh active
- 2006-12-21 TW TW95148218A patent/TWI469788B/zh active
-
2008
- 2008-05-29 IL IL191842A patent/IL191842A0/en unknown
- 2008-06-18 MA MA31048A patent/MA30064B1/fr unknown
- 2008-06-19 EC EC2008008560A patent/ECSP088560A/es unknown
- 2008-07-02 NO NO20082988A patent/NO20082988L/no not_active Application Discontinuation
-
2013
- 2013-04-25 JP JP2013092845A patent/JP6239851B2/ja active Active
-
2014
- 2014-10-08 JP JP2014207464A patent/JP6178772B2/ja active Active
- 2014-10-16 US US14/516,016 patent/US20150037420A1/en not_active Abandoned
-
2015
- 2015-12-22 US US14/977,801 patent/US20160120935A1/en not_active Abandoned
-
2016
- 2016-06-09 JP JP2016115579A patent/JP2016216467A/ja not_active Withdrawn
-
2018
- 2018-01-17 US US15/873,473 patent/US20180140662A1/en not_active Abandoned
- 2018-11-29 CL CL2018003398A patent/CL2018003398A1/es unknown
-
2020
- 2020-03-10 US US16/813,864 patent/US20200206306A1/en not_active Abandoned
-
2022
- 2022-06-07 US US17/834,014 patent/US20220296675A1/en not_active Abandoned
-
2024
- 2024-11-22 US US18/956,119 patent/US20250082718A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023134518A (ja) | 透過性増強された医薬組成物 | |
| JP7653218B2 (ja) | 送達増強エピネフリン組成物 | |
| AR039744A1 (es) | Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada | |
| JP7431724B2 (ja) | 増強された透過を有する医薬組成物 | |
| AR111679A2 (es) | Formulación farmacéutica de liberación controlada, procesos, usos, método | |
| FI2341905T4 (fi) | Pitkävaikutteisia formulaatioita, joissa käytetään ei-vesipitoisia kantajia | |
| PE20081297A1 (es) | Forma de dosificacion transdermica resistente a la manipulacion | |
| DK1553927T3 (da) | Gel-stabiliserede, nanopartikulære aktivstof-sammensætninger | |
| AR068185A1 (es) | Composiciones de tabletas de desintegracion oral de lamotrigina | |
| EP1786400A4 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE CONTROLLED RELEASE OF BIOLOGICAL ACTIVE SUBSTANCES | |
| JP2026027254A (ja) | 増強された送達のエピネフリン及びプロドラッグ組成物 | |
| CO5570662A2 (es) | Formulacion farmaceutica que contiene 3-(3-dimetilamino-1- etil-2-metil-propil) fenol y proporciona una liberacion retardada del ingrediente activo | |
| AR040722A1 (es) | Formulaciones y formas de dosificacion para la administracion controlada de topiramato | |
| CY1122771T1 (el) | Φαρμακοτεχνικες μορφες παρατεταμενης αποδεσμευσης για τη χορηγηση πρωτεϊνων στον οφθαλμο και μεθοδοι για την παρασκευη αυτων | |
| MX336930B (es) | Formulaciones de ganaxolona y metodos para la manufactura y el uso de las mismas. | |
| AR041370A1 (es) | Formulaciones farmaceuticas solidas que comprenden telmisartano y su preparacion | |
| AR045076A1 (es) | Composicion de pelicula que se disuelve oralmente, pelicula multicomponente que se disuelve oralmente, uso de la composicion de pelicula y de la pelicula que se disuelve oralmente para preparar un medicamento, forma de dosificacion oral y procedimiento para preparar la composicion de pelicula que se | |
| WO2005009357A3 (en) | Controlled release compositions | |
| AR052153A1 (es) | Composiciones y metodos para la estabilizacion de ingredientes farmaceuticos activos | |
| AR082024A1 (es) | Formulacion de anticuerpo contra ox40l humano | |
| CR9704A (es) | Composicion farmaceutica de liberacion modificada, proceso de preparacion y metodo para emplear la misma. | |
| ECSP088560A (es) | Formulacion de liberacion sostenida que comprende octreotida y dos o mas polimeros de polilactido-co-glicolido | |
| JP2013177406A5 (enExample) | ||
| PE20091949A1 (es) | Formulacion farmaceutica solida con liberacion retardada | |
| AR107212A1 (es) | Compuestos tópicos de matriz polimérica que comprenden una alta concentración de hialuronato de sodio biofermentado y sus usos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |